US00D860451S

(12) United States Design Patent

Smith et al.

(10) Patent No.: US D860,451 S
(45) Date of Patent: ** Sep. 17, 2019

(54) **IMPLANT REMOVAL TOOL**

(71) Applicant: **Intarcia Therapeutics, Inc.**, Boston, MA (US)

(72) Inventors: **Jay S. Smith**, Wellesley Hills, MA (US); **Michael R. Cole**, Stratham, NH (US)

(73) Assignee: **Intarcia Therapeutics, Inc.**, Boston, MA (US)

(**) Term: **15 Years**

(21) Appl. No.: **29/566,822**

(22) Filed: **Jun. 2, 2016**

(51) **LOC (12) Cl.** **24-02**

(52) **U.S. Cl.**
USPC **D24/143**

(58) **Field of Classification Search**
USPC D24/143–144, 147, 133, 155; D8/57; 604/59–60, 73
(Continued)

(56) **References Cited**

U.S. PATENT DOCUMENTS

1,655,158 A 1/1928 Muir
2,110,208 A 3/1938 Eggert
(Continued)

FOREIGN PATENT DOCUMENTS

DE 000000635692 A 9/1936
EP 0079405 5/1983
(Continued)

OTHER PUBLICATIONS

Palmeri et al., "5-Fluorouracil and recombinant α-interferon-2a in the treatment of advanced colorectal carcinoma: a dose optimization study," J. Chemotherapy 2(5):327-330 (Oct. 1990).
(Continued)

Primary Examiner — Wan Laymon
(74) *Attorney, Agent, or Firm* — Brian C. Trinque; Gordon R. Moriarty; Lathrop Gage LLP

(57) **CLAIM**

The ornamental design for an implant removal tool, as shown and described.

DESCRIPTION

FIG. **1** is a perspective view of an embodiment of a design for an implant removal tool;
FIG. **2** is a front view of the design for the implant removal tool of FIG. **1**;
FIG. **3** is a back view of the design for the implant removal tool of FIG. **1**;
FIG. **4** is a first side view of the design for the implant removal tool of FIG. **1**;
FIG. **5** is a second side view of the design for the implant removal tool of FIG. **1**;
FIG. **6** is a top view for the design for the implant removal tool of FIG. **1**;
FIG. **7** is a bottom view for the design of the implant removal tool of FIG. **1**;
FIG. **8** is a perspective view of another embodiment of a design for an implant removal tool;
FIG. **9** is a front view of the design for the implant removal tool of FIG. **8**;
FIG. **10** is a back view of the design for the implant removal tool of FIG. **8**;
FIG. **11** is a first side view of the design for the implant removal tool of FIG. **8**;
FIG. **12** is a second side view of the design for the implant removal tool of FIG. **8**;
FIG. **13** is a top view for the design for the implant removal tool of FIG. **8**; and,
FIG. **14** is a bottom view for the design of the implant removal tool of FIG. **8**.
Any broken lines shown in the drawings form no part of the claimed design.

1 Claim, 14 Drawing Sheets



(58) **Field of Classification Search**
CPC A61M 37/0069; A61B 17/3468; A61B 17/3403; A61B 17/221
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2,168,437	A		8/1939	Buercklin
2,531,724	A		11/1950	Cevasco
2,643,653	A		6/1953	Heidrich
D179,537	S		1/1957	Floyd et al.
3,016,895	A		1/1962	Sein
3,025,991	A		3/1962	Gillon
3,122,162	A		2/1964	Sands
3,463,157	A	*	8/1969	Hunt A61D 1/00 D24/143
3,523,906	A		8/1970	Vrancken et al.
3,538,916	A		11/1970	Groff
3,620,216	A		11/1971	Szymanski
3,625,214	A		12/1971	Higuchi
3,632,768	A		1/1972	Bergy et al.
3,669,104	A		6/1972	Wyatt
3,691,090	A		9/1972	Kitajima et al.
D226,915	S		5/1973	Huggins
3,732,865	A		5/1973	Higuchi et al.
3,737,337	A		6/1973	Sehnoring et al.
3,766,915	A		10/1973	Rychlik
3,773,919	A		11/1973	Boswell
3,797,492	A		3/1974	Place
3,869,549	A		3/1975	Geller
3,891,570	A		6/1975	Fukushima et al.
D236,035	S		7/1975	Ciencewicki
3,960,757	A		6/1976	Morishita et al.
3,987,790	A		10/1976	Eckenhoff et al.
3,995,631	A		12/1976	Higuchi et al.
3,995,632	A		12/1976	Nakano et al.
4,008,719	A		2/1977	Theeuwes et al.
4,034,756	A		7/1977	Higuchi et al.
4,078,060	A		3/1978	Benson et al.
4,105,030	A		8/1978	Kercso
4,111,201	A		9/1978	Theeuwes
4,111,202	A		9/1978	Theeuwes
4,111,203	A		9/1978	Theeuwes
4,203,439	A		5/1980	Theeuwes
4,211,771	A		7/1980	Witkowski et al.
4,221,862	A		9/1980	Naito et al.
4,223,674	A		9/1980	Fluent et al.
4,243,030	A		1/1981	Lynch et al.
D258,837	S		4/1981	Spranger et al.
D259,458	S		6/1981	Fuller et al.
4,305,927	A		12/1981	Theeuwes et al.
4,310,516	A		1/1982	Chang et al.
4,340,054	A		7/1982	Michaels
4,350,271	A		9/1982	Eckenhoff
4,373,527	A		2/1983	Fischell
4,376,118	A		3/1983	Daher et al.
4,384,975	A		5/1983	Fong
4,389,330	A		6/1983	Tice et al.
4,439,196	A		3/1984	Higuchi
4,444,498	A		4/1984	Heinemann
4,451,253	A		5/1984	Harman
4,455,143	A		6/1984	Theeuwes et al.
4,455,145	A		6/1984	Theeuwes
4,474,572	A		10/1984	McNaughton et al.
4,530,840	A		7/1985	Tice et al.
4,552,561	A		11/1985	Eckenhoff et al.
4,588,614	A		5/1986	Lauchenauer
4,594,108	A		6/1986	Greminger, Jr. et al.
4,597,753	A		7/1986	Turley
4,609,374	A		9/1986	Ayer
4,639,244	A		1/1987	Rizk et al.
4,655,462	A		4/1987	Balsells
4,657,533	A	*	4/1987	Oscarsson A61M 37/0069 604/60
4,673,405	A		6/1987	Guittard et al.
4,675,184	A		6/1987	Hasegawa et al.
4,695,623	A		9/1987	Stabinsky
4,727,138	A		2/1988	Goeddel et al.
4,734,284	A		3/1988	Terada et al.
4,737,437	A		4/1988	Gutsell, Jr. et al.
4,743,449	A		5/1988	Yoshida et al.
4,753,651	A		6/1988	Eckenhoff
4,762,791	A		8/1988	Goeddel et al.
4,765,989	A		8/1988	Wong et al.
4,783,337	A		11/1988	Wong et al.
4,818,517	A		4/1989	Kwee et al.
4,820,267	A		4/1989	Harman
4,820,638	A		4/1989	Swetly et al.
4,826,144	A		5/1989	Balsells
4,830,344	A		5/1989	Balsells
4,834,708	A		5/1989	Pillari
4,845,196	A		7/1989	Cowling
4,847,079	A		7/1989	Kwan
4,851,228	A		7/1989	Zentner et al.
4,840,896	A		8/1989	Reddy
4,865,845	A		9/1989	Eckenhoff et al.
4,871,094	A		10/1989	Gall et al.
4,873,080	A		10/1989	Brickl et al.
4,874,388	A		10/1989	Wong et al.
4,876,781	A		10/1989	Balsells
4,882,166	A		11/1989	Graham et al.
4,885,166	A		12/1989	Meyer et al.
4,886,668	A		12/1989	Haslam et al.
4,892,778	A		1/1990	Theeuwes et al.
4,893,795	A		1/1990	Balsells
4,897,471	A		1/1990	Stabinsky
4,907,788	A		3/1990	Balsells
4,915,366	A		4/1990	Balsells
4,915,949	A		4/1990	Wong et al.
4,915,954	A		4/1990	Ayer et al.
4,917,887	A		4/1990	Hauptmann et al.
4,917,895	A		4/1990	Lee et al.
4,923,805	A		5/1990	Reddy et al.
4,927,687	A		5/1990	Nuwayser
4,929,554	A		5/1990	Goeddel et al.
4,931,285	A		6/1990	Edgren et al.
4,934,666	A		6/1990	Balsells
4,940,465	A		7/1990	Theeuwes et al.
4,940,588	A		7/1990	Sparks et al.
4,952,402	A		8/1990	Sparks et al.
4,957,119	A		9/1990	de Nijs
4,961,253	A		10/1990	Balsells
4,964,204	A		10/1990	Balsells
4,969,884	A		11/1990	Yum
4,974,821	A		12/1990	Balsells
4,976,966	A		12/1990	Theeuwes et al.
4,994,028	A		2/1991	Leonard et al.
5,004,689	A		4/1991	Fiers et al.
5,006,346	A		4/1991	Theeuwes et al.
5,019,382	A		5/1991	Cummins, Jr.
5,019,400	A		5/1991	Gombotz et al.
5,023,088	A		6/1991	Wong et al.
5,024,842	A		6/1991	Edgren et al.
5,030,216	A		7/1991	Theeuwes et al.
5,034,229	A		7/1991	Magruder et al.
5,053,014	A		10/1991	Van Heugten
5,056,718	A		10/1991	Wakefield
5,057,318	A		10/1991	Magruder et al.
5,059,423	A		10/1991	Magruder et al.
5,066,436	A		11/1991	Komen et al.
5,071,642	A		12/1991	Lahr et al.
5,072,070	A		12/1991	Balsells
5,079,388	A		1/1992	Balsells
5,090,962	A		2/1992	Landry et al.
5,091,188	A		2/1992	Haynes
5,108,078	A		4/1992	Balsells
5,110,596	A		5/1992	Magruder et al.
5,112,614	A		5/1992	Magruder et al.
5,113,938	A		5/1992	Clayton
5,117,066	A		5/1992	Balsells
D326,718	S		6/1992	Maxwell
5,118,666	A		6/1992	Habener
5,120,306	A		6/1992	Gosselin
5,120,712	A		6/1992	Habener
5,120,832	A		6/1992	Goeddel et al.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,122,128	A	6/1992	Cardinal et al.
5,122,377	A	6/1992	Miller
5,126,142	A	6/1992	Ayer et al.
5,126,147	A	6/1992	Silvestri et al.
5,134,244	A	7/1992	Balsells
5,137,727	A	8/1992	Eckenhoff
D329,278	S	9/1992	Gallup
5,147,295	A	9/1992	Stewart
5,151,093	A	9/1992	Theeuwes et al.
5,160,122	A	11/1992	Balsells
5,160,743	A	11/1992	Edgren et al.
5,161,806	A	11/1992	Balsells
5,180,591	A	1/1993	Margruder et al.
5,190,765	A	3/1993	Jao et al.
5,192,273	A	3/1993	Bierman
5,203,849	A	4/1993	Balsells
5,204,108	A	4/1993	Illum
5,207,752	A	5/1993	Sorensen et al.
5,209,746	A	5/1993	Balaban et al.
5,213,809	A	5/1993	Wright et al.
5,213,810	A	5/1993	Steber
5,219,572	A	6/1993	Sivaramakrishnan
5,221,278	A	6/1993	Linkwitz et al.
5,223,265	A	6/1993	Wong
5,225,205	A	7/1993	Orsolini
5,231,176	A	7/1993	Goeddel et al.
5,234,424	A	8/1993	Yum et al.
5,234,692	A	8/1993	Magruder et al.
5,234,693	A	8/1993	Magruder et al.
5,234,695	A	8/1993	Hobbs et al.
5,250,026	A	10/1993	Ehrlich et al.
5,252,338	A	10/1993	Jao et al.
5,260,069	A	11/1993	Chen
D342,855	S	1/1994	Butler, II
5,278,151	A	1/1994	Korb et al.
5,279,544	A	1/1994	Gross et al.
5,279,554	A	1/1994	Turley
5,279,555	A	1/1994	Lifshey
5,279,608	A	1/1994	Cherif Cheikh
5,284,655	A	2/1994	Bogdansky et al.
5,288,501	A	2/1994	Nümberg et al.
5,288,502	A	2/1994	Mcginity et al.
5,290,271	A	3/1994	Jernberg
5,300,079	A	4/1994	Niezink et al.
5,300,302	A	4/1994	Tachon et al.
5,308,348	A	5/1994	Balaban et al.
5,312,335	A	5/1994	McKinnon et al.
5,312,389	A	5/1994	Theeuwes et al.
5,312,390	A	5/1994	Wong
5,318,558	A	6/1994	Linkwitz et al.
5,318,780	A	6/1994	Viegas et al.
5,320,616	A	6/1994	Magndu et al.
5,324,280	A	6/1994	Wong et al.
5,336,057	A	8/1994	Fukuda et al.
5,336,505	A	8/1994	Ng et al.
5,348,544	A	9/1994	Sweeney et al.
5,352,662	A	10/1994	Brooks et al.
5,368,588	A	11/1994	Bettinger
5,368,863	A	11/1994	Eckenhoff et al.
5,371,089	A	12/1994	Rattan
5,374,620	A	12/1994	Clark et al.
5,385,738	A	1/1995	Yamahira et al.
5,385,887	A	1/1995	Yim et al.
5,395,319	A	3/1995	Hirsch et al.
5,407,609	A	4/1995	Tice et al.
D358,644	S	5/1995	Park
5,411,951	A	5/1995	Mitchell
5,413,572	A	5/1995	Wong et al.
5,413,672	A	5/1995	Hirotsuji et al.
5,424,286	A	6/1995	Eng
5,428,024	A	6/1995	Chu et al.
5,429,602	A	7/1995	Hauser
5,439,688	A	8/1995	Orsolini et al.
5,443,459	A	8/1995	Wong et al.
5,445,829	A	8/1995	Paradissis et al.
5,456,679	A	10/1995	Balaban et al.
5,458,888	A	10/1995	Chen
5,464,929	A	11/1995	Bezwada et al.
5,472,708	A	12/1995	Chen
5,478,564	A	12/1995	Wantier et al.
5,484,403	A	1/1996	Yoakum et al.
5,486,365	A	1/1996	Takado et al.
5,498,255	A	3/1996	Wong et al.
5,511,355	A	4/1996	Dingler
5,512,293	A	4/1996	Landrau et al.
5,512,549	A	4/1996	Chen et al.
5,514,110	A	5/1996	Teh
5,529,914	A	6/1996	Hubbell et al.
5,531,736	A	7/1996	Wong et al.
5,540,665	A	7/1996	Mercado et al.
5,540,912	A	7/1996	Roorda et al.
5,541,172	A	7/1996	Labrie et al.
5,542,682	A	8/1996	Goldstein et al.
5,543,156	A	8/1996	Roorda et al.
5,545,618	A	8/1996	Buckley et al.
5,556,642	A	9/1996	Kobayashi et al.
5,557,318	A	9/1996	Gabriel
5,558,637	A	9/1996	Allonen et al.
5,569,289	A	10/1996	Yoon
5,571,525	A	11/1996	Roorda et al.
5,574,008	A	11/1996	Johnson et al.
5,574,137	A	11/1996	Gray et al.
5,580,578	A	12/1996	Oshlack et al.
5,589,167	A	12/1996	Cleland et al.
5,595,751	A	1/1997	Bezwada
5,595,759	A	1/1997	Wright et al.
5,597,579	A	1/1997	Bezwada et al.
5,602,010	A	2/1997	Hauptmann et al.
5,605,688	A	2/1997	Himmler et al.
5,607,687	A	3/1997	Bezwada et al.
5,609,885	A	3/1997	Rivera et al.
5,613,954	A	3/1997	Nelson et al.
5,614,221	A	3/1997	Fjellstrom
5,614,492	A	3/1997	Habener
5,618,552	A	4/1997	Bezwada et al.
5,620,698	A	4/1997	Bezwada et al.
5,620,705	A	4/1997	Dong et al.
5,630,796	A	5/1997	Bellhouse et al.
5,633,011	A	5/1997	Dong et al.
5,635,213	A	6/1997	Nystrom et al.
5,639,477	A	6/1997	Maruyama et al.
5,639,640	A	6/1997	Reddy et al.
5,645,850	A	7/1997	Bezwada et al.
5,648,088	A	7/1997	Bezwada et al.
5,650,173	A	7/1997	Ramstack et al.
5,654,008	A	8/1997	Herbert et al.
5,654,010	A	8/1997	Johnson et al.
5,656,297	A	8/1997	Bernstein et al.
5,656,299	A	8/1997	Kino et al.
5,658,593	A	8/1997	Orly et al.
5,660,847	A	8/1997	Magruder et al.
5,660,858	A	8/1997	Parikh et al.
5,660,861	A	8/1997	Jao et al.
5,667,808	A	9/1997	Johnson et al.
5,668,170	A	9/1997	Gyory
5,672,549	A	9/1997	Minami et al.
5,676,942	A	10/1997	Testa et al.
5,686,097	A	11/1997	Taskovich et al.
5,688,801	A	11/1997	Mesens et al.
5,690,925	A	11/1997	Gray et al.
5,690,952	A	11/1997	Magruder et al.
5,695,463	A	12/1997	Cherif-Cheikh
5,697,113	A	12/1997	Shatz et al.
5,697,914	A	12/1997	Brimhall
5,698,213	A	12/1997	Jamiolkowski et al.
5,700,486	A	12/1997	Canal et al.
5,700,583	A	12/1997	Jamiolkowski et al.
5,703,200	A	12/1997	Bezwada et al.
5,707,644	A	1/1998	Illum
5,711,967	A	1/1998	Juch
5,713,847	A	2/1998	Howard, III et al.
5,718,922	A	2/1998	Herrero-Vanrell
5,725,497	A	3/1998	Woodruff et al.
5,728,088	A	3/1998	Margruder et al.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,728,396	A	3/1998	Peery et al.
5,733,572	A	3/1998	Unger et al.
5,736,159	A	4/1998	Chen et al.
5,738,845	A	4/1998	Imakawa
5,747,058	A	5/1998	Tipton et al.
5,756,450	A	5/1998	Hahn et al.
5,767,251	A	6/1998	Reddy et al.
5,770,231	A	6/1998	Mesens et al.
5,782,396	A	7/1998	Mastri et al.
5,792,477	A	8/1998	Rickey et al.
5,795,591	A	8/1998	Lee et al.
5,795,779	A	8/1998	McCormick et al.
5,807,876	A	9/1998	Armistead et al.
5,810,769	A	9/1998	Schlegel et al.
5,814,323	A	9/1998	Lyle
D399,821	S	10/1998	Tyneski et al.
5,817,129	A	10/1998	Labrecque et al.
5,827,297	A	10/1998	Boudjema
5,830,501	A	11/1998	Dong et al.
5,836,935	A	11/1998	Ashton et al.
5,843,891	A	12/1998	Sherman
5,844,017	A	12/1998	Jamiolkowski et al.
5,851,451	A	12/1998	Takechi et al.
5,858,746	A	1/1999	Hubbell et al.
5,859,150	A	1/1999	Jamiolkowski et al.
5,861,166	A	1/1999	Eckenhoff
5,871,770	A	2/1999	Margruder et al.
5,871,778	A	2/1999	Kino et al.
5,874,388	A	2/1999	Hsu
5,876,746	A	3/1999	Jona et al.
5,882,676	A	3/1999	Lee et al.
D408,917	S	4/1999	Hacker
5,904,935	A	5/1999	Eckenhoff et al.
5,906,599	A	5/1999	Kaldany
5,906,816	A	5/1999	Soos et al.
5,906,830	A	5/1999	Farinas et al.
5,908,621	A	6/1999	Glue et al.
5,916,598	A	6/1999	Rickey et al.
5,922,253	A	7/1999	Herbert et al.
5,928,666	A	7/1999	Farinas et al.
5,932,547	A	8/1999	Stevenson et al.
5,938,654	A	8/1999	Wong et al.
5,939,286	A	8/1999	Johnson et al.
5,942,223	A	8/1999	Bazer et al.
5,942,253	A	8/1999	Gombotz et al.
5,945,126	A	8/1999	Thanoo et al.
5,948,430	A	9/1999	Zerbe et al.
5,951,521	A	9/1999	Mastrototaro et al.
5,958,909	A	9/1999	Habener
D415,073	S	10/1999	Meehan et al.
5,962,023	A	10/1999	Jamiolkowski et al.
5,965,168	A	10/1999	Mesens et al.
5,972,370	A	10/1999	Eckenhoff et al.
5,972,373	A	10/1999	Yajima et al.
5,976,109	A	11/1999	Heruth
5,980,945	A	11/1999	Ruiz
5,981,719	A	11/1999	Woiszwillo et al.
5,984,890	A	11/1999	Gast et al.
5,985,305	A	11/1999	Peery et al.
5,989,463	A	11/1999	Tracy et al.
5,997,527	A	12/1999	Gumucio et al.
5,997,902	A	12/1999	Maruyama et al.
6,007,805	A	12/1999	Foster et al.
6,017,545	A	1/2000	Modi
6,022,561	A	2/2000	Carlsson et al.
6,023,802	A	2/2000	King
6,029,361	A	2/2000	Newman
6,053,927	A	4/2000	Hamas
6,060,450	A	5/2000	Soos et al.
6,069,133	A	5/2000	Carlo et al.
6,074,377	A	6/2000	Sanfilippo, II
6,074,660	A	6/2000	Jamiolkowski et al.
6,074,673	A	6/2000	Guillen
6,100,346	A	8/2000	Jamiolkowski et al.
6,110,503	A	8/2000	Rickey et al.
D430,671	S	9/2000	Shute
6,113,938	A	9/2000	Chen et al.
6,113,947	A	9/2000	Cleland et al.
6,120,787	A	9/2000	Gustafsson et al.
6,124,261	A	9/2000	Stevenson et al.
6,124,281	A	9/2000	Lewis et al.
6,127,520	A	10/2000	Ueda et al.
6,129,761	A	10/2000	Hubbell
6,130,200	A	10/2000	Brodbeck et al.
6,132,420	A	10/2000	Dionne et al.
6,133,249	A	10/2000	Hills
6,133,429	A	10/2000	Davis et al.
6,146,139	A	11/2000	Harrison, III
6,147,168	A	11/2000	Jamiolkowski et al.
6,156,331	A	12/2000	Peery et al.
6,172,046	B1	1/2001	Albrecht
6,174,547	B1	1/2001	Dong et al.
6,177,096	B1	1/2001	Zerbe et al.
6,183,461	B1	2/2001	Matsuura et al.
6,187,095	B1	2/2001	Labrecque et al.
6,190,350	B1	2/2001	Davis et al.
6,190,700	B1	2/2001	Okada et al.
6,190,702	B1	2/2001	Takada et al.
6,191,102	B1	2/2001	DiMarchi et al.
6,204,022	B1	3/2001	Johnson et al.
6,217,893	B1	4/2001	Pellet et al.
6,217,906	B1	4/2001	Gumucio et al.
6,217,908	B1	4/2001	Mathiowitz et al.
6,218,431	B1	4/2001	Schoen et al.
6,224,894	B1	5/2001	Jamiolkowski et al.
6,235,712	B1	5/2001	Stevenson et al.
6,245,349	B1	6/2001	Yiv et al.
6,245,357	B1	6/2001	Edgren et al.
6,248,112	B1	6/2001	Gambale et al.
6,251,435	B1	6/2001	Jamiolkowski et al.
D445,975	S	7/2001	Stratford
6,258,377	B1	7/2001	New et al.
6,261,584	B1	7/2001	Peery et al.
6,268,343	B1	7/2001	Knudsen et al.
6,270,700	B1	8/2001	Ignatious
6,270,787	B1	8/2001	Ayer
6,277,413	B1	8/2001	Sankaram
6,283,949	B1	9/2001	Roorda
6,284,264	B1	9/2001	Zerbe et al.
6,284,725	B1	9/2001	Coolidge et al.
6,284,727	B1	9/2001	Kim et al.
6,287,295	B1	9/2001	Chen et al.
6,329,336	B1	12/2001	Bridon et al.
6,331,311	B1	12/2001	Brodbeck et al.
6,372,218	B1	4/2002	Cummins, Jr.
6,372,256	B2	4/2002	Jamiolkowski et al.
6,375,978	B1	4/2002	Kleiner et al.
6,395,292	B2	5/2002	Peery et al.
6,402,716	B1	6/2002	Ryoo
6,403,655	B1	6/2002	Bezwada et al.
6,419,952	B2	7/2002	Wong et al.
6,428,517	B1	8/2002	Hochman et al.
6,433,144	B1	8/2002	Morris et al.
6,436,091	B1	8/2002	Harper et al.
6,447,522	B2	9/2002	Gambale et al.
6,451,974	B1	9/2002	Hansen
6,458,385	B2	10/2002	Jamiolkowski et al.
6,458,387	B1	10/2002	Scott et al.
6,458,924	B2	10/2002	Knudsen et al.
6,461,605	B1	10/2002	Cutler et al.
6,464,688	B1	10/2002	Harper et al.
6,468,961	B1	10/2002	Brodbeck et al.
6,471,688	B1	10/2002	Harper et al.
6,472,512	B1	10/2002	LaFleur et al.
6,478,768	B1	11/2002	Kneer
6,485,706	B1	11/2002	McCoy et al.
6,495,164	B1	12/2002	Ramstack et al.
6,506,724	B1	1/2003	Hiles et al.
6,508,808	B1	1/2003	Carr et al.
6,514,500	B1	2/2003	Bridon et al.
6,514,517	B2	2/2003	Jamilolkowski et al.
6,524,305	B1	2/2003	Peterson et al.
6,528,093	B1	3/2003	Kamei et al.
6,528,486	B1	3/2003	Larsen et al.

(56) **References Cited**

U.S. PATENT DOCUMENTS

D472,896	S		4/2003	Peiker
6,541,021	B1		4/2003	Johnson et al.
6,544,239	B2		4/2003	Kinsey et al.
6,544,252	B1		4/2003	Theeuwes et al.
6,547,250	B1		4/2003	Noble
6,551,613	B1		4/2003	Dong et al.
6,569,420	B2		5/2003	Chen et al.
6,572,890	B2		6/2003	Faour et al.
6,579,851	B2		6/2003	Goeke et al.
6,589,157	B2		7/2003	Fontayne et al.
6,592,508	B1		7/2003	Ravins et al.
6,592,887	B2		7/2003	Zerbe et al.
6,593,295	B2		7/2003	Bridon et al.
6,607,529	B1		8/2003	Jones et al.
6,626,863	B1		9/2003	Berler
6,635,268	B2		10/2003	Peery et al.
6,645,192	B2		11/2003	Kenison
6,667,061	B2		12/2003	Ramstack et al.
6,670,368	B1		12/2003	Breault et al.
6,673,767	B1		1/2004	Brodbeck et al.
6,682,522	B2		1/2004	Carr et al.
6,703,225	B1		3/2004	Kojima et al.
6,703,359	B1		3/2004	Young et al.
6,706,689	B2		3/2004	Coolidge et al.
6,709,671	B2		3/2004	Zerbe et al.
6,720,407	B1		4/2004	Hughes et al.
6,730,328	B2		5/2004	Maskiwicz et al.
6,752,753	B1		6/2004	Hoskins et al.
D492,995	S	*	7/2004	Rue D24/133
6,767,887	B1		7/2004	Hoffmann et al.
6,821,949	B2		11/2004	Bridon et al.
6,833,256	B1		12/2004	Pontzer et al.
6,835,194	B2		12/2004	Johnson et al.
6,840,931	B2		1/2005	Peterson et al.
6,849,708	B1		2/2005	Habener
6,849,714	B1		2/2005	Bridon et al.
6,858,576	B1		2/2005	Young et al.
6,872,700	B1		3/2005	Young et al.
6,875,748	B2		4/2005	Manthorpe et al.
6,887,470	B1		5/2005	Bridon et al.
6,887,849	B2		5/2005	Bridon et al.
6,899,887	B2		5/2005	Ayer
6,899,898	B2		5/2005	Albayrak
6,902,744	B1		6/2005	Kolterman et al.
6,903,186	B1		6/2005	Dong
6,913,767	B1		7/2005	Cleland et al.
6,923,800	B2		8/2005	Chen et al.
6,924,264	B1		8/2005	Prickett et al.
6,939,556	B2		9/2005	Lautenbach
6,956,026	B2		10/2005	Beeley et al.
6,960,192	B1		11/2005	Flaherty et al.
6,969,702	B2		11/2005	Bertilsson et al.
6,976,981	B2		12/2005	Ayer
6,989,366	B2		1/2006	Beeley et al.
6,992,065	B2		1/2006	Okumu
6,997,922	B2		2/2006	Theeuwes et al.
7,008,439	B1		3/2006	Janzen et al.
7,014,636	B2		3/2006	Gilbert
7,022,674	B2		4/2006	DeFelippis et al.
7,041,646	B2		5/2006	Pan et al.
7,074,423	B2		7/2006	Fereira et al.
7,084,243	B2		8/2006	Glaesner et al.
7,101,567	B1		9/2006	Sano et al.
7,101,843	B2		9/2006	Glaesner et al.
7,112,335	B2		9/2006	Lautenbach
7,115,569	B2		10/2006	Beeley et al.
7,138,375	B2		11/2006	Beeley et al.
7,138,486	B2		11/2006	Habener et al.
7,141,547	B2		11/2006	Rosen et al.
7,144,863	B2		12/2006	DeFelippis et al.
7,153,825	B2		12/2006	Young et al.
7,157,555	B1		1/2007	Beeley et al.
7,163,688	B2		1/2007	Peery et al.
7,163,697	B2		1/2007	Hanes et al.
7,199,217	B2		4/2007	DiMarchi et al.
7,205,409	B2		4/2007	Pei et al.
7,207,982	B2		4/2007	Dionne et al.
7,214,206	B2		5/2007	Rue et al.
7,241,457	B2		7/2007	Chen et al.
7,258,869	B1		8/2007	Berry et al.
D555,589	S		11/2007	Hussaini et al.
7,297,761	B2		11/2007	Beeley et al.
7,316,680	B2		1/2008	Gilbert
7,393,827	B2		7/2008	Nadler
7,407,499	B2		8/2008	Trautman
7,442,682	B2		10/2008	Kitaura et al.
7,456,254	B2		11/2008	Wright et al.
7,459,432	B2		12/2008	Cowley et al.
7,521,423	B2		4/2009	Young et al.
7,563,871	B2		7/2009	Wright et al.
7,589,169	B2		9/2009	Bolotin
7,604,647	B2		10/2009	Chen
7,612,176	B2		11/2009	Wright et al.
7,632,256	B2		12/2009	Mosler et al.
7,635,463	B2		12/2009	Bolotin et al.
D608,447	S		1/2010	Meyer et al.
7,655,254	B2		2/2010	Dennis et al.
7,655,257	B2		2/2010	Peery et al.
7,666,835	B2		2/2010	Bloom et al.
7,682,356	B2		3/2010	Alessi et al.
7,727,519	B2		6/2010	Moran
7,731,947	B2		6/2010	Eliaz et al.
7,736,665	B2		6/2010	Patel et al.
7,741,269	B2		6/2010	Young et al.
7,766,924	B1		8/2010	Bombard et al.
7,790,140	B2		9/2010	Bolotin
7,825,091	B2		11/2010	Bloom et al.
7,829,109	B2		11/2010	Chen et al.
7,833,543	B2		11/2010	Gibson et al.
7,879,028	B2		2/2011	Alessi et al.
7,879,794	B2		4/2011	Weyer et al.
7,919,109	B2		4/2011	Berry et al.
7,928,065	B2		4/2011	Young et al.
D638,478	S		5/2011	Block
7,959,938	B2		6/2011	Rohloff et al.
7,964,183	B2		6/2011	Eliaz et al.
8,039,432	B2		10/2011	Bridon et al.
8,048,438	B2		11/2011	Berry et al.
8,052,996	B2		11/2011	Lautenbach et al.
8,058,233	B2		11/2011	Cowley et al.
8,101,576	B2		1/2012	Bloom
8,114,430	B2		2/2012	Rohloff et al.
8,114,437	B2		2/2012	Rohloff et al.
8,158,150	B2		4/2012	Lautenbach et al.
8,173,150	B2		5/2012	Berry et al.
8,190,702	B1		5/2012	Sakata et al.
8,202,836	B2		6/2012	Moore et al.
8,206,745	B2		6/2012	Rohloff et al.
8,211,467	B2		7/2012	Rohloff et al.
8,217,001	B2		7/2012	Cowley et al.
8,231,859	B2		7/2012	Bolotin et al.
8,251,946	B2		8/2012	Bardy
8,257,682	B2		9/2012	Bolotin et al.
8,257,691	B2		9/2012	Eliaz et al.
8,262,667	B1		9/2012	Silver et al.
8,263,545	B2		9/2012	Levy et al.
8,263,736	B2		9/2012	Berry
8,268,341	B2		9/2012	Berry et al.
8,273,365	B2		9/2012	Lautenbach et al.
8,273,713	B2		9/2012	Pittner et al.
D669,589	S		10/2012	Delaey
8,277,776	B2		10/2012	Bolotin et al.
8,278,267	B2		10/2012	Weyer et al.
8,288,338	B2		10/2012	Young et al.
8,298,561	B2		10/2012	Alessi et al.
8,299,025	B2		10/2012	Alessi et al.
8,343,140	B2		1/2013	Alessi et al.
8,367,095	B2		2/2013	Lautenbach et al.
8,372,424	B2		2/2013	Berry et al.
D678,889	S		3/2013	Chiu
8,398,967	B2		3/2013	Eliaz et al.
8,440,226	B2		5/2013	Rohloff et al.
8,454,552	B2		6/2013	Bardy
8,460,694	B2		6/2013	Rohloff et al.

(56) **References Cited**

U.S. PATENT DOCUMENTS

8,470,353 B2 6/2013 Lautenbach et al.
8,722,037 B2 5/2014 Veenstra et al.
8,747,412 B2 6/2014 Bae et al.
8,801,700 B2 8/2014 Alessi et al.
8,815,802 B2 8/2014 Kalthoff et al.
8,858,621 B2 10/2014 Oba et al.
8,865,202 B2 10/2014 Zerbe et al.
8,888,745 B2 11/2014 Van Der Graaf et al.
8,926,595 B2 1/2015 Alessi et al.
8,940,316 B2 1/2015 Alessi et al.
8,992,961 B2 3/2015 Berry et al.
8,992,962 B2 3/2015 Lautenbach et al.
9,044,209 B2 6/2015 Dayton et al.
9,078,900 B2 7/2015 Kuzma et al.
9,095,553 B2 8/2015 Rohloff et al.
9,241,722 B2 1/2016 Yu
D750,764 S 3/2016 DeSocio
9,332,995 B2 5/2016 Russo
9,526,763 B2 12/2016 Rohloff et al.
9,539,200 B2 1/2017 Lautenbach
9,572,889 B2 2/2017 Alessi et al.
D789,539 S 6/2017 Kleiner et al.
D789,540 S 6/2017 Gyorgy
9,682,127 B2 6/2017 Alessi et al.
RE46,577 E 10/2017 Collins et al.
9,889,085 B1 2/2018 Alessi et al.
2001/0012511 A1 8/2001 Bezwada et al.
2001/0021377 A1 9/2001 Jamiolkowski et al.
2001/0021822 A1 9/2001 Ayer
2001/0022974 A1 9/2001 Ayer
2001/0026793 A1 10/2001 Jamiolkowski et al.
2001/0027311 A1 10/2001 Chen et al.
2001/0031940 A1 10/2001 Loos
2001/0031790 A1 11/2001 Beisswenger
2001/0036472 A1 11/2001 Wong et al.
2001/0040326 A1 11/2001 Balczun
2002/0001631 A1 1/2002 Okumu
2002/0004481 A1 1/2002 Cleland et al.
2002/0012818 A1 1/2002 Ruppi et al.
2002/0034532 A1 3/2002 Brodbeck et al.
2002/0037309 A1 3/2002 Jaworowicz et al.
2002/0048600 A1 4/2002 Bhatt et al.
2002/0077599 A1 6/2002 Wojcik
2002/0098180 A1 7/2002 Lei
2002/0136848 A1 9/2002 Yoshii et al.
2002/0137666 A1 9/2002 Beeley et al.
2002/0141985 A1 10/2002 Pittner et al.
2002/0197185 A1 12/2002 Jamiolkowski et al.
2002/0197235 A1 12/2002 Moran
2003/0007992 A1 1/2003 Gibson et al.
2003/0032947 A1 2/2003 Harper et al.
2003/0040699 A1 2/2003 Talling et al.
2003/0044467 A1 3/2003 Brodbeck et al.
2003/0045454 A1 3/2003 Okumu et al.
2003/0059376 A1 3/2003 Libbey et al.
2003/0059471 A1 3/2003 Compton et al.
2003/0060425 A1 3/2003 Ahlem et al.
2003/0078616 A1 4/2003 Fey et al.
2003/0078618 A1 4/2003 Fey et al.
2003/0097121 A1 5/2003 Jolly et al.
2003/0104063 A1 6/2003 Babcock et al.
2003/0108608 A1 6/2003 Laridon et al.
2003/0108609 A1 6/2003 Berry et al.
2003/0113380 A1 6/2003 Ramstack et al.
2003/0114837 A1 6/2003 Peterson et al.
2003/0118660 A1 6/2003 Rickey et al.
2003/0135153 A1 7/2003 Hagemeier
2003/0138403 A1 7/2003 Drustrup
2003/0138491 A1 7/2003 Tracy et al.
2003/0157178 A1 8/2003 Chen et al.
2003/0170289 A1 9/2003 Chen et al.
2003/0180364 A1 9/2003 Chen et al.
2003/0186858 A1 10/2003 Arentsen
2003/0191099 A1 10/2003 Bohlmann et al.
2003/0211974 A1 11/2003 Brodbeck et al.
2003/0215515 A1 11/2003 Truong-Le et al.
2003/0220617 A1 11/2003 Dickerson
2003/0233101 A1 12/2003 Lubock et al.
2004/0001689 A1 1/2004 Goldsmith et al.
2004/0001889 A1 1/2004 Chen et al.
2004/0002442 A1 1/2004 Pan et al.
2004/0022859 A1 2/2004 Chen et al.
2004/0024068 A1 2/2004 Levy et al.
2004/0024069 A1 2/2004 Chen et al.
2004/0029784 A1 2/2004 Hathaway
2004/0039376 A1 2/2004 Peery et al.
2004/0047888 A1 3/2004 Kenison et al.
2004/0097906 A1 5/2004 Fereira et al.
2004/0101557 A1 5/2004 Gibson et al.
2004/0102762 A1 5/2004 Gilbert
2004/0115236 A1 6/2004 Chan et al.
2004/0142867 A1 7/2004 Oi et al.
2004/0142902 A1 7/2004 Struijker-Boudier
2004/0151753 A1 8/2004 Chen et al.
2004/0157951 A1 8/2004 Wolf
2004/0198654 A1 10/2004 Glaesner et al.
2004/0199140 A1 10/2004 Rue et al.
2004/0209801 A1 10/2004 Brand et al.
2004/0215133 A1 10/2004 Weber et al.
2004/0224903 A1 11/2004 Berry et al.
2004/0225113 A1 11/2004 LaFleur et al.
2004/0243106 A1 12/2004 Ayer
2004/0265273 A1 12/2004 Li et al.
2004/0266683 A1 12/2004 Hathaway et al.
2004/0266692 A1 12/2004 Young et al.
2005/0004557 A1 1/2005 Russell
2005/0008661 A1 1/2005 Fereira et al.
2005/0009742 A1 1/2005 Bertilsson et al.
2005/0010196 A1 1/2005 Fereira et al.
2005/0010942 A1 1/2005 Kim et al.
2005/0070883 A1 3/2005 Brown et al.
2005/0070927 A1 3/2005 Feinberg
2005/0079200 A1 4/2005 Rathenow et al.
2005/0079202 A1 4/2005 Chen et al.
2005/0095284 A1 5/2005 Trautman
2005/0101943 A1 5/2005 Ayer et al.
2005/0106214 A1 5/2005 Chen
2005/0112188 A1 5/2005 Eliaz et al.
2005/0118206 A1 6/2005 Luk et al.
2005/0118221 A1 6/2005 Blakely et al.
2005/0131386 A1 6/2005 Freeman et al.
2005/0131389 A1 6/2005 Peterson et al.
2005/0143749 A1 6/2005 Zalenski et al.
2005/0175701 A1 8/2005 Pan et al.
2005/0201980 A1 9/2005 Moran
2005/0215475 A1 9/2005 Ong et al.
2005/0216087 A1 9/2005 Zucherman et al.
2005/0266087 A1 12/2005 Junnarkar et al.
2005/0271702 A1 12/2005 Wright et al.
2005/0276856 A1 12/2005 Fereira et al.
2005/0281879 A1 12/2005 Chen et al.
2006/0013879 A9 1/2006 Brodbeck et al.
2006/0014678 A1 1/2006 Cowley et al.
2006/0030526 A1 2/2006 Liu et al.
2006/0069029 A1 3/2006 Kolterman et al.
2006/0073182 A1 4/2006 Wong et al.
2006/0084604 A1 4/2006 Kitaura et al.
2006/0084922 A1 4/2006 Botha
2006/0094652 A1 5/2006 Levy et al.
2006/0094693 A1 5/2006 Aziz et al.
2006/0106399 A1 5/2006 Taras et al.
2006/0141040 A1 6/2006 Chen et al.
2006/0142234 A1 6/2006 Chen et al.
2006/0160736 A1 7/2006 Nadler
2006/0178304 A1 8/2006 Juul-Mortensen et al.
2006/0193918 A1 8/2006 Rohloff et al.
2006/0216242 A1 9/2006 Rohloff et al.
2006/0224145 A1 10/2006 Gills
2006/0233841 A1 10/2006 Brodbeck et al.
2006/0246138 A1 11/2006 Rohloff et al.
2006/0251618 A1 11/2006 Dennis et al.
2006/0263433 A1 11/2006 Ayer et al.
2006/0264890 A1 11/2006 Moberg et al.
2006/0280795 A1 12/2006 Penhasi et al.

(56) **References Cited**

U.S. PATENT DOCUMENTS

2006/0293232	A1	12/2006	Levy et al.	
2007/0027105	A1	2/2007	Junnarkar et al.	
2007/0141102	A1	6/2007	De Graaff et al.	
2007/0149011	A1	6/2007	Kent et al.	
2007/0166352	A1	7/2007	Wright et al.	
2007/0248572	A1	10/2007	Moran et al.	
2007/0281024	A1	12/2007	Lautenbach et al.	
2008/0020016	A1	1/2008	Li et al.	
2008/0038316	A1	2/2008	Wong et al.	
2008/0064636	A1	3/2008	Bloom et al.	
2008/0065090	A1	3/2008	Scribner et al.	
2008/0091176	A1	4/2008	Alessi	
2008/0110515	A1	5/2008	Angelosanto et al.	
2008/0112994	A1	5/2008	Junnarkar et al.	
2008/0200383	A1	8/2008	Jennings et al.	
2008/0207512	A1	8/2008	Roth et al.	
2008/0208194	A1	8/2008	Bickenbach	
2008/0226625	A1	9/2008	Berry	
2008/0226689	A1	9/2008	Betty et al.	
2008/0260838	A1	10/2008	Hokenson et al.	
2008/0260840	A1	10/2008	Alessi et al.	
2008/0269725	A1	10/2008	Deem et al.	
2008/0312157	A1	12/2008	Levy et al.	
2009/0012463	A1	1/2009	Beelen et al.	
2009/0022727	A1	1/2009	Houston et al.	
2009/0036364	A1	2/2009	Levy et al.	
2009/0042781	A1	2/2009	Petersen et al.	
2009/0074734	A1	3/2009	Rottiers	
2009/0087408	A1	4/2009	Berry et al.	
2009/0156474	A1	6/2009	Roth et al.	
2009/0163447	A1	6/2009	Maggio	
2009/0186817	A1	7/2009	Ghosh et al.	
2009/0202481	A1	8/2009	Li et al.	
2009/0202608	A1	8/2009	Alessi et al.	
2009/0209460	A1	8/2009	Young et al.	
2009/0210019	A1	8/2009	Kim et al.	
2009/0215694	A1	8/2009	Kolterman et al.	
2009/0234392	A1	9/2009	Dziedzic	
2009/0247463	A1	10/2009	Wright et al.	
2009/0254143	A1	10/2009	Tweden et al.	
2009/0286723	A1	11/2009	Levy et al.	
2009/0312246	A1	12/2009	Baron et al.	
2010/0092566	A1	4/2010	Alessi et al.	
2010/0094252	A1	4/2010	Wengreen et al.	
2010/0105627	A1	4/2010	Salama et al.	
2010/0144621	A1	6/2010	Kim et al.	
2010/0185184	A1	7/2010	Alessi et al.	
2010/0297209	A1	11/2010	Rohloff et al.	
2010/0298807	A1	11/2010	Jansen et al.	
2010/0298840	A1	11/2010	Schwartz	
2010/0331868	A1	12/2010	Bardy	
2010/0331878	A1*	12/2010	Kleinwachter	A61B 17/3468 606/205
2011/0076317	A1	3/2011	Alessi et al.	
2011/0091527	A1	4/2011	Moonen et al.	
2011/0104111	A1	5/2011	Rohloff et al.	
2011/0152181	A1	6/2011	Alsina-Fernandez et al.	
2011/0152182	A1	6/2011	Alsina-Fernandez et al.	
2011/0160708	A1	6/2011	Berry et al.	
2011/0166554	A1	7/2011	Alessi et al.	
2011/0264077	A1	10/2011	Rohloff et al.	
2011/0306549	A1	12/2011	Tatarkiewicz et al.	
2012/0208755	A1	8/2012	Leung	
2012/0303045	A1	11/2012	Cooper et al.	
2013/0030417	A1	1/2013	Alessi	
2013/0034210	A1	2/2013	Rohloff et al.	
2013/0052237	A1	2/2013	Eliaz et al.	
2013/0296661	A1	11/2013	Bornzin et al.	
2013/0324977	A1	12/2013	Vanderpool	
2014/0058409	A1	2/2014	Bratlie	
2014/0058425	A1	2/2014	Porat	
2014/0121741	A1	5/2014	Bennett et al.	
2014/0163057	A1	6/2014	Patel et al.	
2014/0236162	A1	8/2014	Barongan	
2014/0257272	A1	9/2014	Clark, III et al.	
2014/0324067	A1	10/2014	Emken et al.	
2014/0378900	A1	12/2014	Alessi et al.	
2015/0001118	A1	1/2015	Selepack et al.	
2015/0057227	A1	2/2015	Leung	
2015/0133791	A1	5/2015	Sato et al.	
2015/0231062	A1	8/2015	Lautenbach et al.	
2015/0231256	A1	8/2015	Berry et al.	
2015/0297509	A1	10/2015	Schwarz	
2015/0359553	A1	12/2015	Harnisch	
2016/0022582	A1	1/2016	Alessi et al.	
2016/0030337	A1	2/2016	Kuzma et al.	
2016/0158577	A1*	6/2016	Escarguel	A61M 37/0069 600/1
2016/0354115	A1	12/2016	Smith et al.	
2016/0354305	A1	12/2016	Alessi et al.	
2017/0056476	A1	3/2017	Rohloff et al.	
2017/0079906	A1	3/2017	Alessi et al.	
2017/0119854	A1	5/2017	Alessi et al.	
2017/0119855	A1	5/2017	Berry et al.	
2017/0181964	A1	6/2017	Lautenbach et al.	
2017/0252409	A1	9/2017	Leung	
2017/0273706	A1	9/2017	Mirza et al.	
2017/0319470	A1	11/2017	Eliaz et al.	
2017/0319662	A1	11/2017	Berry et al.	
2017/0348392	A1	12/2017	Rohloff	
2017/0368145	A1	12/2017	Alessi et al.	
2018/0009871	A1	1/2018	Blackwell et al.	
2018/0185451	A1	7/2018	Young et al.	
2018/0368875	A1*	12/2018	Castillo	A61B 17/3468

FOREIGN PATENT DOCUMENTS

EP	0254394		1/1988
EP	0295411		12/1988
EP	0304107	A1	2/1989
EP	0368339		5/1990
EP	0373867		6/1990
EP	0431942		6/1991
EP	0486959	A1	5/1992
EP	0497575	A1	8/1992
EP	0521586	A1	1/1993
EP	0596161	A1	5/1994
EP	0379147		9/1994
EP	0627231		12/1994
EP	0631794	A1	1/1995
EP	0729747		5/1997
EP	0771817		5/1997
EP	0596161	B1	2/1998
EP	0841359		5/1998
EP	0767689		6/1999
EP	1046399		10/2000
EP	1084703		3/2001
EP	1300129	A2	4/2003
EP	1300173	A2	4/2003
EP	1300129	A3	5/2003
EP	1323450	A1	7/2003
EP	1600187		1/2009
EP	2133073	A1	12/2009
EP	2020990		9/2010
FR	640907		7/1928
FR	2616665	A2	12/1988
GB	1049104		11/1966
GB	1518683		7/1978
GB	2138298	B	11/1986
GB	2501400		10/2013
GB	2501400	A	10/2013
JP	H02124814	A	5/1990
JP	H07196479	A	8/1995
JP	09-509346	A	9/1997
JP	1997/509346		9/1997
JP	9241153		9/1997
JP	2006/213727	A	8/2006
NL	8901004	A	11/1990
NL	9000948	A	11/1990
NL	9100160		8/1992
NL	9100160	A	8/1992
NZ	592113		8/2012
TW	200634060		10/2006
WO	WO1989003678	A1	5/1989

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	WO1990013285 A1	11/1990
WO	WO1990013361 A1	11/1990
WO	WO1990013780 A1	11/1990
WO	WO 91/07160	5/1991
WO	WO1992019241 A1	11/1992
WO	WO 93/06819	4/1993
WO	WO 93/06821	4/1993
WO	WO 93/008832	5/1993
WO	WO 93/09763	5/1993
WO	WO 93/23083	11/1993
WO	WO 94/09743	5/1994
WO	WO1994010982 A1	5/1994
WO	WO 94/21262	9/1994
WO	WO 95/01167	1/1995
WO	WO 95/09006	4/1995
WO	WO 95/09007	4/1995
WO	WO1995013799 A1	5/1995
WO	WO 95/34285	12/1995
WO	WO 96/001134	1/1996
WO	WO 96/003116	2/1996
WO	WO1996036317 A1	11/1996
WO	WO 96/39142	12/1996
WO	WO 96/40049	12/1996
WO	WO 96/40139	12/1996
WO	WO 96/40355	12/1996
WO	WO1996040049 A1	12/1996
WO	WO 97/15289	5/1997
WO	WO 97/15296	5/1997
WO	WO 97/28181	8/1997
WO	WO1997031943 A1	9/1997
WO	WO1997044039 A1	11/1997
WO	WO 97/46204	12/1997
WO	WO 97/47339	12/1997
WO	WO 98/00152	1/1998
WO	WO 98/00157	1/1998
WO	WO 98/00158	1/1998
WO	WO 98/02169	1/1998
WO	WO1997041837 A3	2/1998
WO	WO1998007412 A1	2/1998
WO	9813092 A1	4/1998
WO	WO 98/13092 A1	4/1998
WO	WO 98/16250	4/1998
WO	WO 98/17315	4/1998
WO	WO 1998/13091	4/1998
WO	WO 98/20930	5/1998
WO	WO 98/27960	7/1998
WO	WO 98/027962	7/1998
WO	WO 98/27963	7/1998
WO	WO 98/030231	7/1998
WO	WO 98/32463	7/1998
WO	WO1998030231 A1	7/1998
WO	WO 98/42317	10/1998
WO	WO 98/47487	10/1998
WO	WO 98/51282	11/1998
WO	WO 98/58698 A1	12/1998
WO	WO 99/03453	1/1999
WO	WO 99/04767	2/1999
WO	WO 99/004768	2/1999
WO	WO1999012549 A2	3/1999
WO	WO 99/16419	4/1999
WO	WO 99/025728	5/1999
WO	WO 99/29306	6/1999
WO	WO 99/033446	7/1999
WO	WO 99/33449	7/1999
WO	WO 99/39700	8/1999
WO	WO 99/040788	8/1999
WO	WO 99/04659	9/1999
WO	WO 99/062501	12/1999
WO	WO 99/064061	12/1999
WO	WO 00/013663	3/2000
WO	WO 00/029206	5/2000
WO	WO 00/038652	7/2000
WO	WO 00/039280	7/2000
WO	WO 00/040273	7/2000
WO	WO 00/041548	7/2000
WO	WO 00/045790	8/2000
WO	WO 00/054745	9/2000
WO	WO2000059476 A1	10/2000
WO	WO 00/066138	11/2000
WO	WO 00/067728	11/2000
WO	WO2000066087 A2	11/2000
WO	WO2001019345 A1	3/2001
WO	WO 01/28631 A1	4/2001
WO	WO2001028525 A2	4/2001
WO	WO 01/043528	6/2001
WO	WO 01/051041	7/2001
WO	WO 01/68168 A1	9/2001
WO	WO 01/78683	10/2001
WO	WO 02/028366	4/2002
WO	WO 02/036072	5/2002
WO	WO 02/043800	6/2002
WO	WO 02/045752	6/2002
WO	WO 02/47716	6/2002
WO	WO 02/067895	9/2002
WO	WO 02/069983	9/2002
WO	02083216 A1	10/2002
WO	WO 02/76344	10/2002
WO	WO 02/085428	10/2002
WO	WO 03/000230	1/2003
WO	WO 03/007981	1/2003
WO	WO 03/011892	2/2003
WO	WO 03/024357	3/2003
WO	WO 03/024503	3/2003
WO	WO2003020245 A1	3/2003
WO	WO 03/030923	4/2003
WO	WO 03/041684	5/2003
WO	WO 03/041757	5/2003
WO	WO 03/053400	7/2003
WO	WO2003066585 A2	8/2003
WO	WO 03/072113	9/2003
WO	WO 03/072133	9/2003
WO	WO 04/002565	1/2004
WO	WO 2004/026106 A2	4/2004
WO	WO2004034975 A2	4/2004
WO	WO2004035754 A2	4/2004
WO	WO2004035762 A2	4/2004
WO	WO2004036186 A2	4/2004
WO	WO 04/052336	6/2004
WO	WO 04/056338	7/2004
WO	WO 04/089335	10/2004
WO	WO 2004/089458 A1	10/2004
WO	WO2004103342 A2	12/2004
WO	WO 05/048930	6/2005
WO	WO 05/048952	6/2005
WO	WO 05/102293	11/2005
WO	WO2005102293 A1	11/2005
WO	WO2005110425	11/2005
WO	WO 06/017772	2/2006
WO	WO 06/023526	3/2006
WO	WO 2006/077242 A1	7/2006
WO	WO 2006/077250 A1	7/2006
WO	WO 06/081279	8/2006
WO	WO 06/083761	8/2006
WO	WO 06/084139	8/2006
WO	WO 06/086727	8/2006
WO	WO 06/101815	9/2006
WO	WO 06/111169	10/2006
WO	WO2006/131730	12/2006
WO	WO 07/024700	3/2007
WO	WO 07/056681	5/2007
WO	WO 07/075534	7/2007
WO	WO 07/084460	7/2007
WO	WO 2007/082889 A1	7/2007
WO	WO 07/133778	11/2007
WO	WO 07/140416	12/2007
WO	WO 08/021133	2/2008
WO	WO2008041245 A2	4/2008
WO	WO 08/061355	5/2008
WO	WO2008/086086 A2	7/2008
WO	WO 08/133908	11/2008
WO	WO 08/134425	11/2008
WO	WO 09/109927	9/2009
WO	WO2009143265 A2	11/2009
WO	WO2009143285 A2	11/2009

(56) **References Cited**

FOREIGN PATENT DOCUMENTS

WO	WO 2010/045169	A1	4/2010
WO	2011011697	A1	1/2011
WO	WO 2013/004983	A1	1/2013
WO	2013160347	A1	10/2013
WO	WO 2013/184235	A1	12/2013

OTHER PUBLICATIONS

Glumetza Brochure 2009, 13 Pages.
Erowid,"Introduction to the Federal Controlled Substance Analog Act" 2001, 4 pages.
Li et al. ("Glucagon-Like Peptide-I Receptor Agonists Versus Insulin Glargine for Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials" in Current Therapeutic Research, vol. 71, No. 4, Aug. 2010.
Nexplanon_Prescribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright © 2011 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
International Search Report and Written Opinion for PCT Application No. PCT/US2016/035602 dated Nov. 29, 2016.
Akers, et al., "Formulation Design and Development of Parenteral Suspensions," Journal of Parenteral Science & Technology, 41(3): 88-96 (1987).
Alonso, et al., "Determinants of Release Rate of Tetanus Vaccine from Polyester Microspheres," Pharmaceutical Research, 10(7):945-953 (1993).
Beck, et al., "Poly(dl-lactide-co-glycolide)/norethisterone microcapsules: An injectable biodegradable contraceptive," Biology of Reproduction, 28(1): 186-195 (1983).
Bodmeier and McGinity, "Solvent selection in the preparation of poly(dl-lactide) microspheres prepared by the solvent evaporation method," International Journal of Pharmaceutics, 43(1-2): 179-186 (Apr. 1988).
Cha and Pitt, "A one-week subdermal delivery system for l-methadone based on biodegradable microcapsules," Journal of Controlled Release, 7: 69-78 (1988).
Cha and Pitt, "The acceleration of degradation-controlled drug delivery from polyester microspheres," Journal of Controlled Release, 8: 259-265 (1989).
Cohen, et al., "Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres," Pharmaceutical Research, 8(6): 713-720 (1991).
Conti, et al., "Use of polylactic acid for the preparation of microparticulate drug delivery systems," Journal of Microencapsulation, 9(2): 153-166 (1992).
Hodgman, et al., Eds., Handbook of Chemistry and Physics, 35th Edition, 1024-1025 (1953).
Jalil and Nixon, "Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties," Journal of Microencapsulation, 7(3): 297-325 (Jul.-Sep. 1990).
Lee and Timasheff, "The stabilization of proteins by sucrose," J. Biological Chem., 256(14): 7193-7201 (Jul. 1981).
Li, et al., "Prediction of solvent removal profile and effect on properties for peptide-loaded PLGA microspheres prepared by solvent extraction/evaporation method," Journal of Controlled Release, 37: 199-214 (1995).
Maa and Hsu, "Liquid-liquid emulsification by static mixers for use in microencapsulation," Journal of Microencapsulation, 13(4): 419-433 (Jul.-Aug. 1996).
Maulding, et al., "Biodegradable microcapsules: Acceleration of polymeric excipient hydrolytic rate by incorporation of a basic medicament," Journal of Controlled Release, 3: 103-117 (1986).
Mehta, et al.,"Peptide containing microspheres from low molecular weight and hydrophilic poly(d,l-lactide-co-glycolide)," Journal of Controlled Release, 41: 249-257 (1996).
Sah, et al., "A novel method of preparing PLGA microcapsules utilizing methylethyl ketone," Pharmaceutical Research, 13(3): 360-367 (1996).
Sato, et al., "Porous biodegradable microspheres for controlled drug delivery. I. Assessment of processing conditions and solvent removal techniques," Pharmaceutical Research, 5(1): 21-30 (1988).
Szayna, et al., "Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats," Endocrinology, 141(6): 1936-1941 (2000).
Thomasin, et al., "A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation," Eur. J. Pharm. Biopharm., 42(1): 16-24 (1996).
van Santbrink and Fauser, "Urinary follicle-stimulating hormone for normogonadotropic colomiphene-resistant anovulatory infertility: Prospective, randomized comparison between low dose step-up and step-down dose regimens," J. Clin. Endocrin. Metab., 82(11): 3597-3602 (1997).
Tracy et al., "Factors affecting the degradation rate of poly(lactide-co-glycolide) microspheresin vivo and in vitro." Biomaterials. 20(11:): 1057-1062 (1999).
Ertl et al., "Poly (DL-lactide-co-glycolide) microspheres as carriers for peptide vaccines," Vaccine 14(9):879-885.(1996).
Thompson et al., "Biodegradable microspheres as a delivery system for rismorelin porcine, a porcine-growth-hormone-releasing hormone," Journal of Controlled Release 43(1):9-22 (1997).
Bray, "Gut Signals and Energy Balance: Ghrelin, Peptide YY, Leptin, and Amylin," (Dec. 19, 2007) (slides and transcript for presentation at Medscape CME).
"Implantable infusion pumps: technology poised for takeoff," BBI Newsletter 17(12):209-211 (Dec. 1994).
Adamson et al., "Phase I trial and pharmacokinetic study of all-trans-retinoic acid administered on an intermittent schedule in combination with interferon-alpha2a in pediatric patients with refractory cancer," J. Clin. Oncol. 15(11):3330-3337 (Nov. 1997).
Adolf et al., "Monoclonal antibodies and enzyme immunoassays specific for human interferon (IFN) ω1: evidence that IFN-ω1 is a component of human leukocyte IFN," Virology 175(2):410-471 (Apr. 1990).
Adolf et al., "Antigenic structure of human interferon ω1 (Interferon αll 1): comparison with other human interferons," J. Gen. Virol. 68(6):1669-1676 (Jun. 1987).
Adolf et al., "Purification and characterization of natural human interferon ω1," J. Bio. Chem. 265(16):9290-9295 (Jun. 1990).
Adolf et al., "Human interferon ω1: isolation of the gene, expression in Chinese hamster ovary cells and characterization of the recombinant protein," Biochim. Biophys. Acta 108(9):167-174 (Jun. 1991).
ANDRX Pharmaceuticals, LLC, ANDA for Concerta® Extended-Release Tablets, 6 pages (correspondence dated Sep. 6, 2005).
ASTM International, Annual Book of ASTM Standards, 8.02:208-211, 584-587 (1984).
Ansel et al., "Dosage Form Design: Pharmaceutical and Formulation Considerations," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 3 at 87-92 (7th ed. Lippincott Williams & Wilkins 1999).
Ansel et al., "Modified-Release Dosage Forms and Drug Delivery Systems," Pharmaceutical Dosage Forms and Drug Delivery Systems, Ch. 8 at 229-243 (7th ed. Lippincott Williams & Wilkins 1999).
Aulitzky, "Successful Treatment of Metastatic Renal Cell Carcinoma With a Biologically Active Dose of Recombinant Interferon-Gama," Journal of Clinical Oncology 7(12):1875-1884 (1989).
Hauck, "Engineer's Guide to Plastics," Materials Engineering 5(72):38-45 (Jul. 17, 1972).
Bailon et al., "Rational Design of a Potent, Long-lasting Form of Interferon: A 40 kDa Branched Polyethylene Glycol-conjugated Interferon Alpha-2a for the Treatment of Hepatitis C," Bioconjugate Chemistry 12(2):195-202 (2001).
Bakan et al., "Physicochemical Characterization of a Synthetic Lipid Emulsion for Hepatocyte-Selective Delivery of Lipophilic Compounds: Application to Polyiodinated triglycerides as Contrast Agents for Computed Tomography," J. Pharm. Sci., 85(9):908-914 (1996).
Bakhtiar et al, "Taking Delivery," Soap Perfumery & Cosmetics 76(3):59-65 (2003) (liposomes in cosmetic delivery systems).
Balkwill,F., "Interferons," Lancet 1(8646):1060-1063 (May 1989).

(56) **References Cited**

OTHER PUBLICATIONS

Bauer et al., "Non-aqueous emulsions as vehicles for capsule fillings," Drug Dev. & Industrial Pharmacy 10(5):699-712 (1984).
Bekkering et al., "Estimation of early hepatitis C viral clearance in patients receiving daily interferon and ribavirin therapy using a mathematical model," Hepatology 33(2):419-423 (Feb. 2001).
Bell et al., "Hamster preproglucagon contains the sequence of glucagon and two related peptides," Nature 302:716-718 (1983).
Bell et al, "Impact of moisture on thermally induced denaturation and decomposition of lyophilized bovine somatotropin," Drug Delivery Research & Dev. Biopolymers, (35):201-209 (1995).
Bertoncello et al., "Haematopoietic radioprotection by Cremophor EL: a polyethoxylated castor oil," Int. J. Radiat. Biol. 67(1):57-64 (1995).
Bohlinder et al., "Use and characteristics of a novel lipid particle-forming matrix as a drug-carrier system," Euro. J. Pharm. Sci. 2(4):271-279 (1994).
Bolinger et al., "Recombinant interferon γ for treatment of chronic granulomatous disease and other disorders," Clin. Pharm. 11(10):834-850 (Oct. 1992).
Bonkovsky et al., "Outcomes research in chronic viral hepatitis C: effects of interferon therapy," Can. J. Gastroenterol. 14(Supp. B):21B-29B (Jul.-Aug. 2000).
Borden et al., "Second-generation interferons for cancer: clinical targets," Semin. Cancer Biol. 10(2):125-144 (Apr. 2000).
Boué et al., "Antiviral and antiluteolytic activity of recombinant bovine IFN-ω1 obtained from *Pichia pastoris*," J. Interferon & Cytokine Res. 20:677-683 (2000).
Buckwold et. al. "Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses," Antiviral Res. 73(2):118-25 (Feb. 2007) (Epub Sep. 11, 2006).
Cantor, "Theory of lipid monolayers comprised of mixtures of flexible and stiff amphiphiles in anthermal solvents: fluid phase coexistence," J. Chem. Physics 104(20):8082-8095 (1996).
CAS Number: 56-81-5 (Nov. 16, 1984).
Chang et al., "Biodegradable polyester implants and suspension injection for sustained release of a cognitive enhancer," Pharm. Tech. 20(1):80-84 (1996).
Chapman et al., "Physical Studies of Phospholipids. VI. Thermotropic and Lyotropic Mesomorphism of Some 1,2-Diacylphosphatidylcholines (lecithins)," Chem. & Physics of Lipids 1(5):445-475 (1967).
Chaumeil, "Micronization: a method of improving the bioavailability of poorly soluble drugs," Methods & Findings in Experimental & Clinical Pharmacology 20(3):211-215 (1998).
Clark et al., "The diabetic Zucker fatty rat," Proc. Soc. Exp. Biol. 173(1):68-75 (1983).
Condino-Neto, "Interferon-γ improves splicing efficiency of CYBB gene transcripts in an interferon responsive variant of chronic granulomatous disease due to a splice site consensus region mutation," Blood 95(11):3548-3554 (Jun. 2000).
Darney, "Subdermal progestin implant contraception," Current Opinion in Obstetrics & Gynecology 3:470-476 (1991).
Das et al., "Reviewing Antisense Oligonucleotide Therapy: Part 2, Delivery Issues," BioPharm, 2(11):44-51 (1999).
Dash et al., "Therapeutic applications of implantable drug delivery systems," Journal of Pharmacological and Toxicological Methods, 40(1):1-12 (1998).
Davis et al., "Durability of viral response to interferon alone or in combination with oral ribavirin in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 570).
Deacon et al., "GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion," Am. J. Physiol. Endocrinol. Metab., 282:E873-E879 (2002).
Desai et al., "Protein structure in the lyophilized state: a hydrogen isotope exchange/NMR study with bovine pancreatic trypsin inhibitor," J. Am. Chem. Soc. 116(21):9420-9422 (1994).
Di Marco et al., "Combined treatment of relapse of chronic hepatitis C with high-dose α-2B interferon plus ribavirin for 6 or 12 months," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 569).
Dorr et al., "Phase I-II trial of interferon-alpha 2b by continuous subcutaneous infusion over 28 days," J. Interferon Res. 8:717-725 (1988).
Uhlig et al., "The electro-osmotic actuation of implantable insulin micropumps," J. Biomed. Materials Res. 17:931-943 (1983).
Efendic et al., "Overview of incretin hormones," Horm. Metab. Res., 36(11-12):742-746 (2004).
Eissele et al., "Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," Life Sci., 55(8):629-634 (1994).
Elias et al., "Infusional Interleukin-2 and 5-fluorouracil with subcutaneous interferon-α for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study," Cancer 89(3):597-603 (Aug. 2000).
Eng et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from *Heloderma suspectum* venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas," J. Biol. Chem., 267(11):7402-7405 (1992).
Eng et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from *Heloderma horridum* venom," J. Biol. Chem., 265(33):20259-20262 (1990).
Eppstein et al., "Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor," PNAS USA 82:3688-3692 (1985).
Eros et al., "Multiple phase emulsions as controlled drug delivery therapeutic systems," Proc.-Conf. Colloid Chem. 193-196 (1993).
Fang et al., "The impact of baseline liver histology on virologic response to interferon α-2b±p ribavirin therapy in patients with chronic hepatitis C," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999)(Abstract 572).
Felker et al., "The Rate of Transfer of Unesterified Cholesterol from Rat Erythrocytes to Emulsions Modeling Nascent Triglyceride-Rich Lipoproteins and Chylomicrons Depends on the Degree of Fluidity of the Surface," J. Nutritional Biochem. 4(1):630-634 (1993).
Ferenci et al, "Combination of interferon (IFN) induction therapy and ribavirin in chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 977).
Fontaine et al., "Recovery from chronic hepatitis C in long-term responders to ribarivin plus interferon α," Lancet 356(9223):41 (Jul. 2000).
Fujii et al., "Effect of phosphatidylcholine on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," Int'l J. Pharmaceutics 222(1):57-64 (2001).
Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" Diabetologia 27:599-600 (1984).
Glue et al., "A dose-ranging study of Peg-intron and ribavirin in chronic hepatitis C—safety, efficacy, and virological rationale," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX(Nov. 5-9, 1999)(Abstract 571).
Goke et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells," J. Biol. Chem., 268(26):19650-19655 (1993).
Gonzales et al., "Randomized controlled trial including an initial 4-week 'induction' period during one year of high-dose interferon α-2B treatment for chronic hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 975).
Gosland et al., "A phase I trial of 5-day continuous infusion cisplatin and interferon alpha," Cancer Chemother. Pharmacol. 37(1-2):39-46 (1995).
Grant et al., "Combination therapy with interferon-α plus N-acetyl cysteine for chronic hepatitis C: a placebo controlled double-blind multicentre study," J. Med. Virol. 61(4):439-442 (Aug. 2000).
Gutniak et al., "Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus," N. Engl. J. Med., 326(20):1316-1322 (1992).
Hageman, "The Role of Moisture in Protein Stability, " Drug Dev. & Ind. Pharm. 14(14):2047-2070 (1988).

(56) **References Cited**

OTHER PUBLICATIONS

Heathcote et al., "Peginterferon alfa-2a in Patients With Chronic Hepatitis C and Cirrhosis," New England J. Med. 343(23):1673-1680 (2000).
Heim et al., "Intracellular signaling and antiviral effects of interferons," Dig. Liver Dis. 32(3):257-263 (Apr. 2000).
Heinrich et al., "Pre-proglucagon messenger ribonucleic acid: nucleotide and encoded amino acid sequences of the rat pancreatic complementary deoxyribonucleic acid," Endocrinol., 115:2176-2181 (1984).
Hellstrand et al., "Histamine and cytokine therapy," Acta Oncol. 37(4):347-353 (1998).
Hellstrand et al., "Histamine and the response to IFN-α in chronic hepatitis C," Interferon Cytokine Res. 18(1):21-22 (Jan. 1998).
Hellstrand et al., "Histamine in immunotherapy of advanced melanoma: a pilot study," Cancer Immunol Immunother. 39(6):416-419 (Dec. 1994).
Hisatomi et al., "Toxicity of polyoxyethylene hydrogenated castor oil 60 (HCO-60) in experimental animals," J. Toxicol. Sci., 18(3):1-9 (1993).
Hodoshima et al., "Lipid nanoparticles for delivering antitumor drugs," International Journal of Pharmaceutics, 146(1):81-92 (1997).
Hoffmann-La Roche Inc., Pegasys® (peginterferon alfa-2a), 15 pages (2002).
Horton et al., "Antitumor effects of interferon-omega: in vivo therapy of human tumor xenografts in nude mice" Cancer Res 59(16):4064-4068 (Aug. 1999).
Hubel et al., "A phase I/II study of idarubicin, dexamethasone and interferon-alpha (1-Dexa) in patients with relapsed or refractory multiple myeloma" Leukemia 11 Suppl 5:S47-S51 (Dec. 1997).
Iacobelli et al., "A phase I study of recombinant interferon-alpha administered as a seven-day continuous venous infusion at circadian-rhythm modulated rate in patients with cancer," Am. J. Clin. Oncol. 18(1):27-31 (1995).
IFNB Multiple Sclerosis Study Group, "Interferonβ-1b is effective in relapsing-remitting multiple sclerosis," Neurology 43(4):655-667 (Apr. 1993).
Intermune® Inc., Infergen® (Interferon alfacon-1), 5 pages (2002).
"Introduction to Antibodies", http://www.chemicon.com/resource/ANT101/a1.asp, 8 pages (retrieved May 2, 2007).
Isaacs et al., "Virus interference. I. The interferon," Pro. R. Soc. Lond. B. Biol. Sci. 147:258-267 (1957).
Jain et al., "Controlled delivery of drugs from a novel injectable in situ formed biodegradable PLGA microsphere system," J. Microencapsulation 17(3):343-362 (2000).
Jordan et al., "Guidelines for Antiemetic Treatment of Chemotherapy-Induced Nausea and Vomiting: Past, Present and Future Recommendations," The Oncologist 12(9):1143-1150 (2007).
Kabalnov et al., "Macroemulsion type and stability of alkane-water-phospholipid systems," Abstracts of Papers, Part 1, 210th ACS National Meeting, 0/8412-3222-9, American Chemical Society, Chicago, IL (Aug. 20-24, 1995) (Abstract only).
Kabalnov et al., "Phospholipids as Emulsion Stabilizers.2. Phase Behavior Versus Emulsion Stability," Journal of Colloid and Interface Science 184(1):227-235 (1996).
Khalili et al., "Interferon and ribavirin versus interferon and amantadine in interferon nonresponders with chronic hepatitis C," Am. J. Gastroenterol. 95(5):1284-1289 (May 2000).
Kildsig et al., "Theoretical Justification of Reciprocal Rate Plots in Studies of Water Vapor Transmission through Films," J. Pharma. Sci. 29(11):1634-01637 (Nov. 17, 1970).
Kirkwood et al., "Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684," J. Clin. Oncol. 14(1):7-17 (1996).
Kita et al., "Characterization of a polyethylene glycol conjugate of recombinant human interferon-γ," Drug Des. Deliv. 6(3):157-0167 (Sep. 1990).
Knepp et al, "Identification of antioxidants for prevention of peroxide-mediated oxidation of recombinant human ciliary neurotrophic factor and recombinant human nerve growth factor," J. Pharm. Sci. Tech. 50(3):163-171 (1996).
Knepp et al., "Stability of nonaqueous suspension formulations of plasma derived factor IX and recombinant human alpha interferon at elevated temperatures," Pharma. Res. 15(7):1090-1095 (1998).
Knobler et al., "Systemic α-interferon therapy of multiple sclerosis," Neurology 34(10):1273-1279 (Oct. 1984).
Kovacevic et al., "Treatment of chronic viral hepatitis B in secondary membranoproliferative glomerulonephritis using recombinant α-2 interferon," Maksic Dj Vojnosanit. Pregl. 57(2):235-240 (Mar.-Apr. 2000) (non-English with English abstract).
Kracke et al., "Mx proteins in blood leukocytes for monitoring interferon β-1b therapy in patients with MS," Neurology 54(1):193-199 (Jan. 2000).
Krown et al., "Interferons and interferon inducers in cancer treatment," Semin. Oncol. 13(2):207-217 (1986).
Kubes et al., "Cross-species antiviral and antiproliferative activity of human interferon-ω" J. Interferon Res. 14:57-59 (1994).
Kunzi et al., "Role of interferon-stimulated gene ISG-15 in the interferon-ω-mediated inhibition of human immunodeficiency virus replication," J. Interferon Cytokine Res. 16(11):919-927 (Nov. 1996).
Larsson, "Stability of emulsions formed by polar lipids," Progress in the Chemistry of Fats and Other Lipids 16:163-0169 (1978).
Lee et al., "Dynamics of hepatitis C virus quasispecies turnover during interferon-A treatment," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 974).
Lee, "Therapy of hepatitis C: interferon alfa-2A trials," Hepatology 26: 89S-95S (Sep. 1997) (XP000981288).
Lopez et al., "Mammalian pancreatic preproglucagon contains three glucagon-related peptides," Proc. Natl. Acad. Sci. USA, 80(18):5485-5489 (1983).
Lukaszewski et al., "Pegylated α interferon is an effective treatment for virulent Venezuelan equine encephalitis virus and has profound effects on host immune response to infection," J. Virol. 74(11):5006-5015 (Jun. 2000).
Lund et al., "Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem," Proc. Natl. Acad. Sci. USA, 79(2):345-349 (1982).
Lundberg, "A submicron lipid emulsion coated with amphipathic polyethylene glycol for parenteral administration of paclitaxel (Taxol)," J. Pharm. & Pharmacol. 49(1):16-21 (1997).
Magnuson et al "Enhanced recovery of a secreted mammalian protein from suspension culture of genetically modified tobacco cells," Protein Expression & Purification 7:220-228 (1996).
Malley et al., "Chronic Toxicity and Oncogenicity of N-Methylpyrrolidone (Nmp) in Rats and Mice by Dietary Administration," Drug Chem Toxicol. 24(4):315-38 (Nov. 2001).
Manning et al, "Stability of protein pharmaceuticals," Pharm. Res. 6(11):903-918 (1989).
Marincola et al., "Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer," J. Clinical Oncol. 13(5):1110-1122 (1995) (XP009078965).
Massey, "Interaction of vitamin E with saturated phospholipid bilayers," Biochem. & Biophys. Res. Comms. 106(3):842-847 (1982).
McHutchison et al., "Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C," N. Engl. J. Med. 339(21):1485-1492 (Nov. 1998).
Meier et al., "The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans," Am. J. Physiol. Endocrinol. Metab., 290(6):E1118-E1123 (2006).
Merad et al., "Generation of monocyte-derived dendritic cells from patients with renal cell cancer: modulation of their functional properties after therapy with biological response modifiers (IFN-α plus IL-2 and IL-12)," J. Immunother. 23(3):369-378 (May-Jun. 2000).
Milella et al., "Neutralizing antibodies to recombinant α-interferon and response to therapy in chronic hepatitis C virus infection," Liver 13(3):146-150 (Jun. 1993).

(56) **References Cited**

OTHER PUBLICATIONS

Mohler, "Primer on electrodeposited coatings," Materials Engineering 5:38-45 (1972).
Mojsov, "Structural requirements for biological activity of glucagon-like peptide-I," Int. J. Peptide Protein Research, 40:333-343 (1992).
Morgan, "Structure and Moisture Permeability of Film-Forming Poloyers," Ind. Eng. Chem. 45(10):2296-2306 (1953).
Motzer et al., "Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma," J. Clinical Oncol. 19(5):1312-1319 (2001).
Nauck et al., "Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients," Diabet. Med., 15(11):937-945(1998).
Neumann et al., "Hepatitis C Viral Dynamics In Vivo and the Antiviral Efficacy of Interferon-alpha Therapy," Science 282:103-107 (Dec. 1998).
Nieforth et al., "Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon-α-2a and a polyethylene glycol-modified derivative in healthy subjects," Clin. Pharmacol. Ther. 59(6):636-646 (Jun. 1996).
Norden et al., "Physicochemical characterization of a drug-containing phospholipid-stabilized o / w emulsion for intravenous administration," Eur. J. Pharm. Sci. 13(4):393-401 (2001).
Olaso et al., "Early prediction of lack of response to treatment with interferon and interferon plus ribavirin using biochemical and virological criteria in patients with chronic hepatitis C," Esp. Quimioter. 12(3):220-228 (Sep. 1999) (non-English with English abstract).
Ortiz et al., "A differential scanning calorimetry study of the interaction of α-tocopherol with mixtures of phospholipids," Biochim et Biophys Acta 898(2):214-222 (1987).
Panitch, "Interferons in multiple sclerosis," Drugs 44(6):946-962 (Dec. 1992).
Patzelt et al., "Identification and processing of proglucagon in pancreatic islets," Nature, 282:260-266 (1979).
Peterson et al., "Zucker Diabetic Fatty Rat as a Model for Non-insulin-dependent Diabetes Mellitus," ILAR Journal, 32(3):16-19 (1990).
Peterson et al., "Neuropathic complications in the Zucker diabetic fatty rat (ZDF/Drt-fa)," Frontiers in diabetes research. Lessons from Animal Diabetes III, Shafrir, E. (ed.), pp. 456-458, Smith-Gordon, London (1990).
Pimstone et al., "High dose (780 MIU/52 weeks) interferon monotherapy is highly effective treatment for hepatitis C," Prog. Abstr. Dig. Dis. Week 2000, San Diego, CA (May 21-24, 2000) (Abstract 973).
Plauth et al, "Open-label phase II study of omega interferon in previously untreated HCV infected patients," Hepatology 34(4):A331 (Oct. 1, 2001) (XP004716169) (Abstract Only).
Plauth et al, "Open-label study of omega interferon in previously untreated HCV-infected patients," J. Hepatology 36(Supp. 1):125 (Apr. 2002) (XP002511882) (Abstract Only).
Pohl et al., "Molecular cloning of the helodermin and exendin-4 cDNAs in the lizard. Relationship to vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide and glucagon-like peptide 1 and evidence against the existence of mammalian homologues," J. Biol. Chem., 273(16):9778-9784 (1998).
Poynard et al., "Is an 'a la carte' combined interferon α 2b plus ribavirin possible for the first line treatment in patients with chronic hepatitis C," Hepatology 31(1):211-218 (Jan. 2000).
Poynard et al., "Randomized trial of interferon α 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α 2b plus placebo for 48 weeks for the treatment of chronic infection with hepatitis C virus," Lancet 352(9138):1426-1432 (Oct. 1998).
"Intarcia Presents Positive ITCA 650 Phase 2 Study Results for Type 2 Diabetes at EASD, " Intarcia Therapeutics, Inc. (Sep. 22, 2010) (Press Release).
Quesada et al., "Interferons in Hematological Malignancies", eds. Baron et al., U. Tex. 487-495 (1987).
Quintanar-Guerrero et al., "Applications of the ion-pair concept to hydrophilic substances with special emphasis on peptides," Pharm. Res. 14(2):119-127 (1997).
Rajkumar et al., "Phase I evaluation of radiation combined with recombinant interferon alpha-2a and BCNU for patients with high-grade glioma," Int'l J. Radiat. Oncol. Biol. Phys. 40(2):297-302 (Jan. 15, 1998).
Roche Pharmaceuticals, Roferon®-A (Interferon alfa-2a, recombinant), 22 pages (2003).
Roff et al., "Handbook of Common Polymers", Cleveland Rubber Co. 72 pages (1971).
Rogers et al., "Permeability Valves," Ind. & Eng. Chem. 49(11):1933-1936 (Nov. 17, 1957).
Roman et al., "Cholestasis in the rat by means of intravenous administration of cyclosporine vehicle, Cremophor EL," Transplantation 48(4):554-558 (1989).
Roth et al., "High Dose Etretinate and Interferon-alpha—A Phase I Study in Squamous Cell Carcinomas and Transitional Cell Carcinomas," Acta Oncol. 38(5):613-617 (1999).
Roth et al., "Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity," Endocrinol. 148(12):6054-61 (Dec. 2007).
Schepp et al., "Exendin-4 and exendin-(9-39)NH2: agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH2," Eur. J. Pharmacol., 269(2):183-191 (1994).
Schering Corp., Intron® A for Injection, 6 pages (2001).
Schering Corp., PEG-Intron™ (Peginterferon alfa-2b) Powder for Injection, 29 pages (2003).
Schmalfub et al., "Modification of drug penetration into human skin using microemulsions," J. Controlled Release 46(3):279-285 (1997).
Sen et al., "The interferon system: a bird's eye view of its biochemistry," J. Biol. Chem. 267(8):5017-5020 (Mar. 1992).
Shiffman et al., "A decline in HCV-RNA level during interferon or interferon/ribavirin therapy in patients with virologic nonresponse is associated with an improvement in hepatic histology," Prog. Abstr. 50th Annu. Mtg. Postgrad. Courses Am. Assn. Study Liver Dis., Dallas, TX (Nov. 5-9, 1999) (Abstract 567).
Shima et al., "Serum total bile acid level as a sensitive indicator of hepatic histological improvement in chronic hepatitis C patients responding to interferon treatment," J. Gastroenterol. Hepatol. 15(3):294-299 (Mar. 2000).
Shiratori et al., "Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy," Ann. Int. Med. 132(7):517-524 (Apr. 2000).
Simon et al., "A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon β1a," Neurology 55(2):185-192 (Jul. 2000).
Sparks et al., "Lipoprotein alterations in 10- and 20-week-old Zucker diabetic fatty rats: hyperinsulinemic versus insulinopenic hyperglycemia," Metabolism, 47(11):1315-1324 (1998).
Sulkowski et al., "Peginterferon-α-2a (40kD) and ribavirin in patients with chronic hepatitis C: a phase II open label study," Biodrugs 16(2):105-109 (2002).
Talpaz et al., "Phase I study of polyethylene glycol formulation of interferon alpha-2B (Schering 54031) in Philadelphia chromosome-positive chronic myelogenous leukemia," Blood 98(6):1708-1713 (2001).
Talsania et al., "Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice," Endocrinology 146(9):3748-56 (Sep. 2005).
Tanaka et al., "Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients," Int. J. Cancer 87(5):741-749 (Sep. 2000).
Tong et al., "Prediction of response during interferon α 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison," Hepatology 26(6):1640-01645 (Dec. 1997).
Touza Rey et al., "The clinical response to interferon-γ in a patient with chronic granulomatous disease and brain abscesses due to *Aspergillus fumigatus*," Ann. Med. Int. 17(2):86-87 (Feb. 2000).

(56) **References Cited**

OTHER PUBLICATIONS

Trudeau et al., "A phase I study of recombinant human interferon alpha-2b combined with 5-fluorouracil and cisplatin in patients with advanced cancer," Cancer Chemother. Pharmacol. 35(6):496-500 (1995).
Tseng et al., "Glucose-dependent insulinotropic peptide: structure of the precursor and tissue-specific expression in rat," PNAS USA, 90(5):1992-1996 (1993).
Tsung et al., "Preparation and Stabilization of Heparin/Gelatin Complex Coacervate Microcapsules," J. Pharm. Sci. 86(5):603-7 (May 1997).
Unniappan et al., "Effects of dipeptidyl peptidase IV on the satiety actions of peptide YY," Diabetologia; Clinical and Experimental Diabetes and Metabolism 49(8):1915-1923 (Jun. 27, 2006).
Vokes et al., "A phase I trial of concomitant chemoradiotherapy with cisplatin dose intensification and granulocyte-colony stimulating factor support for advanced malignancies of the chest," Cancer Chemother. Pharmacol. 35(4):304-312 (1995).
Vrabec, "Tympanic membrane perforations in the diabetic rat: a model of impaired wound healing," Otolaryngol. Head Neck Surg., 118(3 Pt. 1):304-308 (1998).
Wang et al., "Preferential interaction of α-tocopherol with phosphatidylcholines in mixed aqueous dispersions of phosphatidylcholine and phosphatidylethanolamine," Eur. J. Biochem. 267(21):6362-6368 (2000).
Wang et al., "Ripple phases induced by α-tocopherol in saturated diacylphosphatidylcholines," Archives of Biochem. & Biophys. 377(2):304-314 (2000).
Wang et al., "The distribution of α-tocopherol in mixed aqueous dispersions of phosphatidylcholine and phosphattidylethanolamine," Biochimica et Biophysica Acta-Biomembranes 1509(1-2):361-372 (2000).
Wang et al, "Parenteral formulations of proteins and peptides: stability and stabilizers," J. Parenter. Sci. Technol. 42(2S):S4-S26 (1988).
Young et al., "Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (*Macaca mulatta*)," Diabetes, 48(5):1026-1034 (1999).
Younossi et al., "The role of amantadine, rimantadine, ursodeoxycholic acid, and NSAIDs, alone or in combination with α interferons, in the treatment of chronic hepatitis C," Semin. Liver Dis. 19(Supp. 1):95-102 (1999).
Yu et al., "Preparation, characterization, and in vivo evaluation of an oil suspension of a bovine growth hormone releasing factor analog," J. Pharm. Sci. 85(4):396-401 (1996).
Zeidner et al., "Treatment of FeLV-induced immunodeficiency syndrome (feLV-FAIDS) with controlled release capsular implantation of 2',3'-dideoxycytidine," Antivir. Res. 11(3):147-0160 (Apr. 1989).
Zein, "Interferons in the management of viral hepatitis," Cytokines Cell Mol. Ther. 4(4):229-241 (Dec. 1998).
Zeuzem et al., "Peginterferon Alfa-2a in Patients with Chronic Hepatitis C," New Engl. J. Med. 343(23):1666-1672 (2000).
Zeuzem et al., "Hepatitis C virus dynamics in vivo: effect of ribavirin and interferon α on viral turnover," Hepatology 28(1):245-252 (Jul. 1998).
Zhang et al., "Report on Large Dosage Interferon to Treat 30 Cases of Viral Encephalitis," J. Clinical Pediatrics 14(2):83-84 (1996).
Zhang et al, "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor," Pharm. Res. 12(10):1447-1452 (1995).
Zheng et al. "Therapeutic Effect of Interferon Varied Dose in Treating Virus Encephalitis," Beijing Med. J. 13(2):80-81 (1998).
Ziesche et al., "A preliminary study of long-term treatment with interferon γ-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis," New Engl. J. Med. 341(17):1264-1269 (Oct. 1999).
Sanofi-Aventis U.S. LLC, Prescribing Information for Adlyxin® (Lixisenatide) Injection, for Subcutaneous Use, rev. Jul. 2016, 31 pages.
Amylin Pharmaceuticals, Inc., Prescribing Information for Byetta® (Exenatide) Injection, rev. Oct. 2009, 34 pages.
Astrazeneca Pharmaceuticals LP, Prescribing Information for Bydureon® (Exenatide Extended-Release for Injectable Suspension), rev. Mar. 2015, 60 pages.
Novo Nordisk A/S, Prescribing Information for Victoza® (Liraglutide [rDNA Origin] Injection), Solution for Subcutaneous Use, v. 1, Jan. 2010, 23 pages.
Glaxosmithkline LLC, Prescribing Information for Tanzeum® (Albiglutide) for Injection, for Subcutaneous Use, rev. Jun. 2014, 55 pages.
Eli Lilly & Company, Prescribing Information for Trulicity® (Dulaglutide) Injection, for Subcutaneous Use, rev. Mar. 2015, 19 pages.
Adolf, "Human interferon omega-a review," Mult. Sclr. 1:S44-47 (1995).
Costantino et al., "Protein Spray Freeze Drying. 2. Effect of Formulation Variables on particle Size and Stability," J. Pharm. Sci. 91:388-395 (2002).
Henry et al., "Comparing ITCA 650, continuous subcutaneous delivery of exenatide via Duros® device, vs. twice daily exenatide injections in metformin-treated type 2 diabetes," oral presentation at the 46th Annual Meeting of the European Association for the Study of Diabetes in Stockholm, Sweden , 21 pages (Sep. 20-24, 2010).
Huggins et al., "Synergistic antiviral effects of ribavirin and the C-nucleoside analogs tiazofurin and selenazofurin against togaviruses, bunyaviruses, and arenaviruses," Antimicrobial Agents & Chemotherapy, 26(4):476-480 (1984).
Ishiwata et al., "Clinical effects of the recombinant feline interferon-omega on experimental parvovirus infection in beagle dogs," J. Vet. Med. Sci. 60(8):911-917 (1998).
Johnson et al., "How interferons fight disease," Sci. Am. 270(5):68-75 (May 1994).
Lublin et al., "Defining the clinical course of multiple sclerosis: results of an international survey," Neurology. 46:907-911 (1996).
Madsbad, "Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)—preclinical and clinical results," Best Practice & Research Clinical Endocrinology & Metabolism 23:463-77 (2009).
Nielsen, "Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes," Drug Discovery Today 10(10):703-710 (May 15, 2005).
Patti et al., "Natural interferon-b treatment of relapsing-remitting and secondary-progressive multiple sclerosis patients: two-year study," Acta. Neurol. Scand. 100:283-289 (1999).
Paty et al., "Interferon beta-1 b is effective in relapsing-remitting multiple sclerosis," Neurology 43:662-667 (1993).
PCT International Search Report for PCT/US2009/000916, 4 pages (Aug. 12, 2009).
"Intarcia Therapeutics Announces Final Results from a Phase 2 Study of Injectable Omega Interferon plus Ribavirin for the Treatment of Hepatitis C Genotype-1," NLV Partners Press Coverage Portfolio News (Apr. 12, 2007) (Press Release).
Quianzon et al., "Lixisenatide-Once-daily Glucagon-like Peptide-1 Diabetes," US Endocrinology 7(2):104-109 (2011).
Ratner et al., "Dose-dependent effects of the one-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metfmmin: a randomized, double-blind, placebo-controlled trial," Diabetic Medicine 27(9):1024-1032 (Sep. 2010).
Roberts et al., "The Evolution of the Type I Interferons 1," J. Interferon Cytokine Res. 18(10):805-816 (Oct. 1998).
Rohloff et al., "DUROS Technology Delivers Peptides and Proteins at Consistent Rate Continuously for 3 to 12 Months," J. Diabetes Sci. & Tech., 2(3):461-467 (May 1, 2008).
"Sequence Listings for International Patent Application Publication No. W02009109927, WIPO Patentscope", http://patentscope.wipo.int/search/docservicepdf_pct/id00000008776887, 1 page (last visited Nov. 14, 2012).

(56) **References Cited**

OTHER PUBLICATIONS

Shire et al., "Challenges in the Development of High Protein Concentration Formulations," J. Pharm. Sci. 93:1390-1402 (2004).
Smith, "Peripheral Neuro-hormones as a Strategy to Treat Obesity," oral presentation at the 2007 Cardiometabolic Health Congress in Boston, MA, pp. 1-35 (Sep. 26-29, 2007).
Written Opinion for International Patent Application No. PCT/US2009/005629 (corresponding to U.S. Appl. No. 12/587,946), 5 pages (Apr. 15, 2011).
Zhang et al., "Efficacy observations of different dosages of interferon to treat 150 Hepatitis B carriers," Current Physician 2(12):45-46 (1997).
Pratley et al., "Targeting Incretins in Type 2 Diabetes: Role of GLP-1 Receptor Agonists and DPP-4 Inhibitors," Rev. Diabet. Stud., 5(2):73-94 (2008).
Gonzalez, et al., "Hemoglobin Alc: A Reliable and Accurate Test for Diabetes Care? A Prospective Study in Mexico," Salud Publica Mex 55:462-468 (2013).
Ahn et al., "A New Approach to Search for the Bioactive Confirmation of Glucagon: Positional Cyclization Scanning" Journal of Medicinal Chemistry, vol. 44, No. 19, (2001): 3109-3116.
Georgios, et al., "Pharmacokinetics and Tolerability of Exenatide Delivered by 7-Day Continuous Subcutaneous Infusion in Healthy Volunteers", Advances in Therapy, Health Communications, Metuchen, NJ, US, vol. 32, No. 7, Jul. 10, 2015, pp. 650-661.
Yu et al., "Glucagon-like peptide 1 based therapy for type 2 diabetes", World Journal of Pediatrics vol. 4, No. 1, Feb. 1, 2008, pp. 8-13.
Taylor et al., "Day-long subcutaneous infusion of exenatide lowers glycemia in patients with type 2 diabetes", Horm Metab Res 37: 627-632 (2005).
Gao et al., "Target-Mediated Pharmacokinetic and Pharmacodynamic Model of Exendin-4 in Rats, Monkeys. And Humans," Drug Metabolism and Disposition, vol. 40, No. 5, pp. 990-997 (2012).
Franchetti et al., "Furanfurin and Thiophenfurin: Two Novel Tiazofurin Analogues, Synthesis, Structure, Antitumor Activity, and Interactions with Inosine Monophosphate Dehydrogenase," J. Medicinal Chem. 38(19):3829-3837 (1995).
Fujii et al., "Effect of phosphatidylehohne on Skin Permeation of Indomethacin from gel prepared with Liquid Paraffin and Hydrogenated Phospholipid," Int'l J. Pharmaceutics 222(1):57-64 (2001).
Fujii et al "Enhancement of skin permeation of miconazole by phospholipid and dodecyl 2-(N, N-dimethylamino) propionate (DDAIP)." Int'l J. Pharmaceutics 234(1-2);121-128 2002).
Luft et al., "Electro-osmotic valve for the controlled administration of drugs," Med. & Biological Engineering & Computing 45-50 (Jan. 1978) (non-English with English abstract).
Gan to Kagaku Ryoho, "Phase II study of recombinant leukocyte A interferon (Ro22-8181) in malignant brain tumors," Cancer & Chemotherapy 12(4):913-920 (Apr. 1985) (non-English with English abstract).
Gappa et al., "Juvenile laryngeal papillomatosis—a case report," Pneumologie 45(11):936-938 (Nov. 1991) (XP009079028) (non-English with English abstract).
Gause et al., "Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer," J. Clin. Oncol. 14(8):2234-2241 (Aug. 1996).
Ghiglione et al., "How glucagon-like is glucagon-like peptide-1?" Disbetologia 27:599-600 (1984).
Croxatto, "Clinical profile of Implanon: a single-rod etonogestrel contraceptive implant," Eur J Contracept Reprod Health Care. Sep. 2000; 5 Suppl 2:21-8.
Implanon_Prescribing Information. Manufactured for Merck Sharp Dohme Corp. Copyright © 2006, 2009, 2012 Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Nexplanon_Presscribing Information. Manufactured for Merck Sharp & Dohme Corp. Copyright ©Merck Sharp & Dohme B.V., a subsidiary of Merck & Co., Inc. Revised Mar. 2016.
Probuphine _Prescribing Information. Distributed by Braeburn Pharmaceuticals, Inc. Revised May 2016.
Henry et al. (2014) "Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes," Journal of Diabetes and Its Complications, 28:393-398.
Schepis et al. (2001) "Which patients with cirrhosis should undergo endoscopic screening for esophageal varices detection," Hepatology, 33(2):333-338.

* cited by examiner



FIG. 1



FIG. 2



FIG. 3



FIG. 4



FIG. 5



FIG. 6



FIG. 7



FIG. 8



FIG. 9



FIG. 10



FIG. 11



FIG. 12



FIG. 13



FIG. 14